

BEST AVAILABLE COPY



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 135 172

A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 84109990.6

(51) Int. Cl.4: A 61 K 31/35

(22) Date of filing: 22.08.84

//C07D311/36

(30) Priority: 24.08.83 JP 155603/83

(71) Applicant: Takeda Chemical Industries, Ltd.
27, Doshomachi 2-chome Higashi-ku
Osaka-shi Osaka, 541(JP)

(43) Date of publication of application:
27.03.85 Bulletin 85/13

(72) Inventor: Yamazaki, Iwao
9-21, Hibarigaoka Yamate 1-chome
Takarazuka Hyogo 665(JP)


(84) Designated Contracting States:
BE CH DE FR GB LI NL SE

(72) Inventor: Sawa, Yoichi
19-11, Sengoku-higashi-machi
Kadoma Osaka 571(JP)

(74) Representative: von Kreisler, Alek, Dipl.-Chem. et al.
Deichmannhaus am Hauptbahnhof
D-5000 Köln 1(DE)

(54) Method for treatment of osteoporosis.

(57) A compound of the formula



wherein R is a hydrogen atom or a hydroxy group is effective
for prevention or treatment of osteoporosis.

EP 0 135 172 A2


-1-

Method for treatment of osteoporosis

This invention relates to a therapeutic means for treatment of osteoporosis.

More particularly, this invention relates to a medicament 5 for prevention or treatment of osteoporosis, which contains a compound of the formula

10



wherein R is a hydrogen atom or a hydroxy group.

Osteoporosis is a disease condition or illness which 15 occurs frequently in postmenopausal females, particularly those in their sixties, and wherein the quantitative loss of bones progresses beyond a certain limit to thereby present some symptoms or risk manifestations. Among its main clinical manifestations are kyphosis, low back pain, and fractures 20 of femoral neck, lower end of the radius, ribs, upper end of the humerus, etc. While the causative factors are variegated, including endocrine disorder and nutritional disorder, apparently the most important cause is a decreased secretion of estrogen due to hypoovarianism in females during the postmenopausal 25 period. Therefore, of all the therapeutic agents for osteoporosis, the theoretically most effective drugs are estrogen preparations.

However, the estrogens so far available are so strong in effect as to cause side effects such as genital bleeding, mastodynia, hepatic disorder, etc. and, for this reason, have not been used recently on as many occasions as in the

5 past. There are other types of therapeutic agents such as calcitonin, vitamin D and calcium preparations, which however are disadvantageous in that they are either only indefinitely effective or ineffective when administered by the oral route.

10 The present inventors have found that the compound of the formula (I) exhibits a milder estrogen activity than the conventional estrogens in the oral regimen and does not cause side effects which are produced by these known drugs but cures osteoporosis by stimulating secretion of

15 calcitonin from the thyroid.

The compounds of the formula (I) which are employed in accordance with the present invention are invariably crystalline compounds which are white to pale yellowish brown in color, and are freely soluble in dimethylformamide

20 and chloroform, soluble in ethanol and acetone and practically insoluble in water. When R in the formula (I) is a hydroxy group, it may be present in any position of the phenyl ring.

These compounds can be produced, for example, by cyclizing a 2,4-dihydroxy-phenyl (with or without a hydroxy group

25 on the benzene ring) benzyl ketone to a benzopyran compound, and some of these compounds are known to have capillary vessel stabilizing activity (French Pharmaceutical Patent No. 1065), therapeutic effective for vascular disorders, inflammatory and vitamin-P deficiency disorders (United

30 States Patent No. 3,352,754) or anticonvulsant activity (Japanese Patent Publication No. 32074/1972), but it has not been known that any of the compounds is useful for the treatment of osteoporosis.

As will be apparent from Test Example 5 which appears

35 hereinafter, all of the compounds of the formula (I) are

sparingly toxic. Thus, in the studies in which the compounds were administered orally or subcutaneously to mice or rats at the technically feasible highest doses (5,000 to 10,000 mg/kg), there occurred no death nor toxic symptoms attributable 5 to the compounds.

On the other hand, Test Examples 1 and 2 presented hereinafter show that 7-hydroxy-isoflavone [hereinafter referred to briefly as compound (I)] and 7,4'-dihydroxy-isoflavone [briefly, compound (II)], which are representative 10 species of the compound represented by the formula (I), have mild estrogenic activity which is suited for the treatment of osteoporosis.

Test Example 1

15 Estrogenic activity of 7-hydroxy-isoflavone in young oophorectomized rats

Sprague-Dawley rats, 33 days old and 11 days after oophorectomy for elimination of endogenous estrogenic activity, were used in groups of 6 to 7 animals. Compound (I) was suspended in a 1% aqueous solution of hydroxypropylcellulose 20 and administered orally for 3 days, while as a representative example of the conventional estrogen drug, estrone was dissolved in sesame oil and administered subcutaneously for 3 days. On the fourth day, each animal was autopsied and its uterine wet weight was recorded. As shown in Table 1, compound 25 (I) at the daily dose levels of 200 mg/kg and 400 mg/kg produced uterine weight increasing effect with a dose-response curve of moderate gradient. In contrast, estrone showed uterine weight increasing effect with a dose-response curve of steep gradient.

10

15

Table 1

Compound	Daily dose (mg/kg)	No. of animals	Uterine wet weight (mg \pm S.D.)
5	0 (control group)	7	35.0 \pm 1.0
	6.25	7	32.8 \pm 1.1
	12.5	7	33.4 \pm 0.9
10	Compound (I)	25	35.1 \pm 0.8
		50	35.3 \pm 1.7
		100	35.9 \pm 1.0
		200	57.9 \pm 1.0*
		400	70.4 \pm 6.7*
15			
	0.0025	7	101.7 \pm 4.6*
	Estrone	0.005	159.8 \pm 9.4*
		0.01	223.3 \pm 12.5*

20 *: Significant as compared with control group (P<0.01)

Test Example 2

25 Estrogenic activity of 7,4'-dihydroxy-isoflavone in young oophorectomized rats

30 Sprague-Dawley rats, 33 days old and 11 days after oophorectomy for elimination of endogenous estrogenic activity, were used in groups of 7 animals. Compound (II) was suspended in a 1% aqueous solution of hydroxypropylcellulose and administered orally. As shown in Table 2, compound (II) at the dose level of 400 mg/kg showed mild uterine weight increasing activity.

Table 2

Daily dose of compound (II) (mg/kg)	No. of animals	Uterine wet weight (mg \pm S.D.)
5		
0 (control group)	7	31.1 \pm 1.1
6.25	7	33.2 \pm 0.8
25	7	32.8 \pm 1.0
100	7	35.3 \pm 1.3
0		
400	7	62.3 \pm 6.0*

*: Significant as compared with control group (P<0.01)

The following Test Examples 3 and 4 show that the compounds of this invention have bone resorption-inhibiting activity which is effective for the treatment of osteoporosis.

Test Example 3

Bone resorption inhibiting activity of 7-hydroxy-isoflavone and 7,4'-dihydroxy-isoflavone in rat fetal long bone culture.

Determination of bone resorption was performed by the method of Raisz [J. Clin. Invest. 44, 103-116 (1965)]. Thus, a Sprague-Dawley rat on the 19th day of pregnancy was subcutaneously injected with 50 μ Ci of ^{45}Ca (isotope of calcium, CaCl_2 solution), and was laparotomized on the following day. The embryos were aseptically taken out, the forelimbs (radius and ulna) were cut off from the trunk under a binocular dissecting microscope, and the connective tissue and cartilage were removed as much as possible to prepare bone samples. Each bone sample was preincubated at 37°C for 24 hours in 0.6 ml of the medium containing 2 mg/ml of bovine serum albumin in BGJ_b medium (Fitton-Jackson modification) [GIBCO Laboratories, Grand Island, NY 14072 U.S.A.]. Then, the sample was further incubated for 3 days in the same medium as above in which 10 $\mu\text{g}/\text{ml}$ or 25 $\mu\text{g}/\text{ml}$ of compound (I) or 10 $\mu\text{g}/\text{ml}$ of compound (II) had been incorporated. Then, the radioactivity of ^{45}Ca in the medium and that of ^{45}Ca in the bone were measured and the percentage (%) of

- 6 -

^{45}Ca released from the bone into the medium was calculated by the following formula.

Percentage (%) of ^{45}Ca released from bone into medium

$$5 = \frac{\text{Count of } ^{45}\text{Ca in medium}}{\text{Count of } ^{45}\text{Ca in medium} + \text{Count of } ^{45}\text{Ca in bone}} \times 100$$

As control, the bones of the embryos from the same litter were similarly incubated in the absence of compound (I) or (II) for 3 days. The mean \pm standard deviation for 10 the six bones per group are shown in Table 3. It is apparent that compounds (I) and (II) suppressed bone resorption.

Table 3

	Concentration of compound	^{45}Ca (%) released
15	Control group	0 20.6 ± 3.8 19.9 ± 5.0
20	Test group 1 Compound (I) 10 $\mu\text{g/ml}$	$16.5 \pm 2.5^*$
Test group 2 Compound (I) 25 $\mu\text{g/ml}$	$13.5 \pm 2.5^*$	
Test group 3 Compound (II) 10 $\mu\text{g/ml}$	$15.9 \pm 1.3^{**}$	

25 * : A significant difference from the control group ($P < 0.001$)

**: A significant difference from the control group ($P < 0.002$)

Test Example 4

Inhibiting activity of 7,4'-dihydroxy-isoflavone to the
bone resorption potentiating action of parathyroid hormone

30 in rat fetal long bone culture.

The bone samples prepared in the same manner as Test Example 3 were pre-incubated for 24 hours in the same medium as that prepared in Test Example 3 which contains bovine serum album in BGJ_b medium (Fitton-Jackson modification).

35 Then, in the concomitant presence of PTH (parathyroid hormone, a bone resorption stimulant) and compound (II), the samples

were further incubated for 3 days and the percentage of ⁴⁵Ca released into the medium was calculated by means of the same formula as that in Test Example 3. The results are shown in Table 4. As control experiments, the same 5 determination was made for a control group using the medium supplemented with PTH alone. It is apparent from Table 4 that compound (II) suppressed PTH-stimulated bone resorption.

Table 4

	<u>Concentration of compound (II)</u>	<u>⁴⁵Ca (%) released</u>
Control group	0	30.8 [±] 4.3
Test group	10 µg/ml	23.5 [±] 3.4*

15 *: A significant difference from the control group (P<0.01)

Test Example 5Acute toxicity

Five-week-old ICR mice and 5-week-old

20 Sprague-Dawley rats were respectively used in groups of 10 males and 10 females, and suspensions of compound (I) or compound (II) in olive oil were administered orally [2,500, 5,000 and 10,000 mg/kg of each compound] or subcutaneously [1,250, 2,500 and 5,000 mg/kg]. The animals were kept under 25 observation for 14 days. None of the groups showed deaths nor toxic symptoms attributable to compound (I) or (II) and, therefore, LD₅₀ values could not be calculated.

The daily dosage of the compound of the formula (I) according to this invention for human beings is generally 30 about 1 to 50 mg/kg and preferably about 5 to 20 mg/kg for oral administration, and about 200 to 600 mg can be orally taken daily, once a day or, if necessary, in 2 to 3 divided doses. The compounds are preferably formulated into such dosage forms as tablets, capsules, etc. by the established 35 pharmaceutical procedure. Such tablets and capsules can

- 8 -

be prepared using suitable excipients such as lactose, starch, etc., binders such as hydroxypropylcellulose, and lubricants such as magnesium stearate. The tablets may be sugar-coated, if necessary.

5 The following preparation examples are given to illustrate the invention in further detail and should not be construed as limiting the scope of the invention.

Example 1 Tablets

	I)	7-Hydroxy-isoflavone	200 g
10	II)	Lactose	15 g
	III)	Starch	44 g
	IV)	Carboxymethylcellulose	10 g
	V)	Magnesium stearate	1 g

The above components I) through V) were admixed to
15 prepare 1000 uncoated tablets with a diameter of 8.5 mm.

Example 2 Capsules

	I)	7,4'-Dihydroxy-isoflavone	200 g
20	II)	Lactose	40 g
	III)	Starch	50 g
	IV)	Hydroxypropylcellulose	7 g
	V)	Magnesium stearate	3 g

The above components I) through V) were admixed and filled into 1000 No. 1 capsules.

25


30

35

- 9 -


What is claimed is:

1. A compound of the formula



wherein R is a hydrogen atom or a hydroxy group for use in prevention or treatment of osteoporosis.

2. A pharmaceutical composition for prevention or treatment of osteoporosis, which contains an effective amount of a compound of the formula



wherein R is a hydrogen atom or a hydroxy group and a pharmaceutical acceptable carrier, vehicle, lubricant or diluent therefor.

3. A pharmaceutical composition according to claim 2, which is in the form of tablet, capsule, granule, fine granule, powder or syrup.

4. A pharmaceutical composition according to claim 2, wherein the osteoporosis is that caused by decreasing secretion of estrogen due to hypoovarianism.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning these documents will not correct the image
problems checked, please do not report these problems to
the IFW Image Problem Mailbox.**